Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.

Eric F MorandMarilyn PikeJoan T MerrillRonald van VollenhovenVictoria P WerthCoburn HobarNikolay DelevVaishali ShahBrian SharkeyThomas WegmanIan CatlettSubhashis BanerjeeShalabh Singhal

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2022)

Deucravacitinib treatment elicited higher response rates for SRI-4 and other end points compared with placebo, with an acceptable safety profile, in adult patients with active SLE.

Keyphrases

double blind
phase ii
placebo controlled
clinical trial
phase iii
open label
systemic lupus erythematosus
study protocol
disease activity
combination therapy
rheumatoid arthritis